Nigel Brown
Corporate Vice President
Business Development and Strategy

As Corporate Vice President of Business Development and Strategy, Dr. Brown is responsible for the evaluation and execution of merger and acquisition opportunities for the corporation, and also leads the Company’s strategic planning process.  He is a member of the Executive Committee and reports to the Chief Executive Officer.

Dr. Brown joined Covance in 2006 and has brought a strong combination of scientific expertise, solid business experience, and a network of business relationships.  Nigel has extensive experience in biomarker development and integrated service development, which are key growth avenues for Covance.

Prior to Covance, Nigel held positions of increasing responsibility over a 15 year period in various international executive positions with The Upjohn Company, SmithKline Beecham Pharmaceuticals, and Phoenix International Life Sciences, which was later bought by MDS Pharma Services.  His most recent role was managing MDS Pharma Services’ Corporate Strategy, Merger & Acquisition, and Global Marketing activities.  His other roles included General Manager of MDS Global Preclinical Operations, which included activities in toxicology, metabolism, biosafety, transgenic animal production, pharmaceutics, and fermentation technologies; and Senior Vice-President, Discovery & Preclinical Services. He was also a team leader and section head in Drug Metabolism and Pharmacokinetics for SmithKline Beecham Pharmaceuticals.

He holds a first degree in chemistry from the University of Oxford, U.K.; an MBA with double distinction from the Open University, U.K.; a Ph.D. in drug metabolism and mass spectrometry from the University of Oxford, U.K.; and held the Nestlé postdoctoral fellowship at M.I.T.  He is extensively published in scientific literature and has served on the boards of several biotech companies.